Crustal thickness and velocity structure across the Moroccan Atlas from long offset wide-angle reflection seismic data: The SIMA experiment

The crustal structure and topography of the Moho boundary beneath the Atlas Mountains of Morocco has been constrained by a controlled source, wide-angle seismic reflection transect: the SIMA experiment. This paper presents the first results of this project, consisting of an almost 700 km long, high-resolution seismic profile acquired from the Sahara craton across the High and the Middle Atlas and the Rif Mountains. The interpretation of this seismic data set is based on forward modeling by raytracing, and has resulted in a detailed crustal structure and velocity model for the Atlas Mountains. Results indicate that the High Atlas features a moderate crustal thickness, with the Moho located at a minimum depth of 35 km to the S and at around 31 km to the N, in the Middle Atlas. Upper crustal shortening is resolved at depth through a crustal root where the Saharan crust underthrusts the northern Moroccan crust. This feature defines a lower crust imbrication that, locally, places the Moho boundary at 40-41 km depth in the northern part of the High Atlas. The P-wave velocity model is characterized by relatively low velocities, mostly in the lower crust and upper mantle, when compared to other active orogens and continental regions. These low deep crustal velocities together with other geophysical observables such as conductivity estimates derived from MT measurements, moderate Bouguer gravity anomaly, high heat flow, and surface exposures of recent alkaline volcanism lead to a model where partial melts are currently emplaced at deep crustal levels and in the upper mantle. The resulting model supports the existence of a mantle upwelling as mechanism that would contribute significantly to sustain the High Atlas topography. However, the detailed Moho geometry deduced in this work should lead to a revision of the exact geometry and position of this mantle feature and will require new modeling effortsThis work has been primarily funded by the Spanish MEC project CGL2007–63889. Additional funding was provided by projects CGL2010–15416, CSD2006-00041, and GL2009–09727 (Spain), CGL2008–03474-E, 07-TOPO_EUROPE_FP-006 (ESF Eurocores) and EAR-0808939 (US, NSF).Peer reviewe

Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

Background: The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients with moderate-to-severe ARDS the impact of early use of NMBAs on 90-day mortality, through propensity score (PS) matching analysis. Methods: We analyzed a convenience sample of patients with COVID-19 and moderate-to-severe ARDS, admitted to 244 intensive care units within the COVID-19 Critical Care Consortium, from February 1, 2020, through October 31, 2021. Patients undergoing at least 2 days and up to 3 consecutive days of NMBAs (NMBA treatment), within 48 h from commencement of IMV were compared with subjects who did not receive NMBAs or only upon commencement of IMV (control). The primary objective in the PS-matched cohort was comparison between groups in 90-day in-hospital mortality, assessed through Cox proportional hazard modeling. Secondary objectives were comparisons in the numbers of ventilator-free days (VFD) between day 1 and day 28 and between day 1 and 90 through competing risk regression. Results: Data from 1953 patients were included. After propensity score matching, 210 cases from each group were well matched. In the PS-matched cohort, mean (± SD) age was 60.3 ± 13.2 years and 296 (70.5%) were male and the most common comorbidities were hypertension (56.9%), obesity (41.1%), and diabetes (30.0%). The unadjusted hazard ratio (HR) for death at 90 days in the NMBA treatment vs control group was 1.12 (95% CI 0.79, 1.59, p = 0.534). After adjustment for smoking habit and critical therapeutic covariates, the HR was 1.07 (95% CI 0.72, 1.61, p = 0.729). At 28 days, VFD were 16 (IQR 0–25) and 25 (IQR 7–26) in the NMBA treatment and control groups, respectively (sub-hazard ratio 0.82, 95% CI 0.67, 1.00, p = 0.055). At 90 days, VFD were 77 (IQR 0–87) and 87 (IQR 0–88) (sub-hazard ratio 0.86 (95% CI 0.69, 1.07; p = 0.177). Conclusions: In patients with COVID-19 and moderate-to-severe ARDS, short course of NMBA treatment, applied early, did not significantly improve 90-day mortality and VFD. In the absence of definitive data from clinical trials, NMBAs should be indicated cautiously in this setting

Correction: Epidemiology and outcomes of early-onset AKI in COVID-19-related ARDS in comparison with non-COVID-19-related ARDS: insights from two prospective global cohort studies (Critical Care, (2023), 27, 1, (3), 10.1186/s13054-022-04294-5)

Following publication of the original article [1], the authors identified that the collaborating authors part of the collaborating author group CCCC Consortium was missing. The collaborating author group is available and included as Additional file 1 in this article